Benefit Ledger · provisional · Medicine & Health
Shares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting.
Current score
+0.00
Ingest update: independent source raised evidence; added a follow-up source. Score remains provisional until review.
Shares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting. Update (2026-09-23): STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks. An FDA advisory panel has endorsed Galleri, a blood test designed by the biotech firm Grail to screen for multiple types of cancer.
Unspecified system mentioned or implied by a news item. Remap to a named release when identified.
News ingest does not infer a named model from the publisher alone. Attribution stays unspecified until a release is identified.
Attribution 0.1000 · Credit share 100% · Unknown
STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
outcome · supported
primary sources
STAT · journalism · 21 Sep 2026
other sources
STAT · journalism · 23 Sep 2026
21 Sep 2026 · 0.00 → 0.00
Auto-published from news ingest.
23 Sep 2026 · 0.00 → 0.00
Ingest update: independent source raised evidence; added a follow-up source.
